Patients with end-stage renal disease (ESRD) have life-limiting illness. Although the mortality risk of ESRD can be mitigated for patients who receive a renal transplant, renal replacement therapy does not confer the same benefit. Given the high rates of mortality and the burdens associated with dialysis, attention to the care that these patients receive at the end of life is important. Using a data set that covers a generous portion of patients in the United States with ESRD, the study by Wachterman and colleagues1 in this issue of JAMA Internal Medicine reveals that the care at the end of life for patients receiving hemodialysis is categorically different from the care at the end of life for patients with other terminal illnesses.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Schwarze ML, Schueller K, Jhagroo RA. Hospice Use and End-of-Life Care for Patients With End-stage Renal Disease: Too Little, Too Late. JAMA Intern Med. 2018;178(6):799–801. doi:https://doi.org/10.1001/jamainternmed.2018.1078
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: